Articles

At ClarityNorth Partners, we have been spending time lately on the growing role of AI in drug discovery, and how it is starting to...

Traditionally, ESG has been treated as a compliance or reputational concern. In today’s deal market, it’s a strategic filter. A way to...

In the early stages of building a life sciences company, the mandate is survival. Founders focus where the risk is greatest: proving the...

Life sciences M&A is uniquely high-stakes. When a strategic buyer steps into an acquisition, they’re not just acquiring molecules....

At ClarityNorth Partners, we often remind our clients of something deceptively simple: value creation doesn’t start on the signing day....

In any M&A process, the signed letter of intent (LOI) is a significant milestone. But it’s not the moment to relax. It’s where the deal...

Introduction: Why Governance Is the Dealmaker’s Edge Acquisition success doesn’t just come down to strategy or price. It comes down to...

As the M&A market grows more competitive, compressed, and capital-conscious, acquirers are demanding more certainty across every stage of...

In M&A, valuation is one of the most debated and most misunderstood topics on the table. Everyone agrees it’s important, but few agree on...

As the world moves aggressively toward decarbonization, the rules of corporate strategy are shifting in real time. Gone are the days when...

In the world of carve-outs, the cleanest deals are rarely the fastest. Buyers want standalone assets, ready to operate on Day 1 without...

Navigating Legacy, Compliance and Culture Acquiring a family‑owned business can offer a powerful strategic leap, particularly in sectors...

For all the boardroom talk about growth, many acquisitions stall in execution. The deal closes, the press release goes out, and then...

Global deal-making has become a core strategy in the race to decarbonize. Companies are buying into low-carbon technologies, shedding...

When it comes to cross-border M&A, due diligence often focuses on the tangible: legal entities, supply chains, tax structures, and ERP...

For founders and CEOs in the life sciences sector, few decisions are as consequential as selling your company. Whether the goal is...

The ink is dry. The press release is out. Everyone’s congratulating each other. Yes, it truly is a great day. But now comes the part that...

Sellers don’t get paid for what they know. They get paid for what the buyer understands. And in carve-outs, few sellers make it easy.  ...

As carve-out activity accelerates in 2025, dealmakers are navigating an increasingly complex landscape. Corporates continue to divest...

In today’s M&A landscape, signing the deal is just the beginning. The real challenge? Turning that signature into value at speed. And...